Suzanne C. van Es

542 total citations
14 papers, 400 citations indexed

About

Suzanne C. van Es is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Suzanne C. van Es has authored 14 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in Suzanne C. van Es's work include Renal cell carcinoma treatment (7 papers), Medical Imaging Techniques and Applications (5 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Suzanne C. van Es is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Medical Imaging Techniques and Applications (5 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Suzanne C. van Es collaborates with scholars based in Netherlands, Italy and Switzerland. Suzanne C. van Es's co-authors include Elisabeth G.E. de Vries, Sjoukje F. Oosting, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, Jourik A. Gietema, Igle J. de Jong, C. Willemien Menke‐van der Houven van Oordt, Johan R. de Jong, Carla M.L. van Herpen and Eline Boon and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The American Journal of Surgical Pathology.

In The Last Decade

Suzanne C. van Es

14 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne C. van Es Netherlands 10 228 161 141 125 79 14 400
Kwon Joong Yong United States 11 360 1.6× 132 0.8× 211 1.5× 158 1.3× 54 0.7× 12 548
Pooja Jain United Kingdom 11 153 0.7× 182 1.1× 293 2.1× 72 0.6× 99 1.3× 26 521
Sietske B.M. Gaykema Netherlands 8 233 1.0× 168 1.0× 70 0.5× 91 0.7× 57 0.7× 8 356
Natalie Charnley United Kingdom 10 95 0.4× 87 0.5× 143 1.0× 69 0.6× 63 0.8× 32 295
Christy Osgood United States 11 129 0.6× 359 2.2× 167 1.2× 132 1.1× 102 1.3× 19 541
Atsuko Kitano Japan 8 204 0.9× 465 2.9× 175 1.2× 102 0.8× 68 0.9× 19 588
K. L. Blackwell United States 7 93 0.4× 311 1.9× 103 0.7× 118 0.9× 71 0.9× 16 438
B. Martell United States 5 144 0.6× 187 1.2× 105 0.7× 142 1.1× 50 0.6× 6 319
Ulrike Fasol Germany 8 65 0.3× 232 1.4× 121 0.9× 130 1.0× 46 0.6× 13 467
Masako Uno Japan 12 130 0.6× 148 0.9× 87 0.6× 180 1.4× 57 0.7× 38 528

Countries citing papers authored by Suzanne C. van Es

Since Specialization
Citations

This map shows the geographic impact of Suzanne C. van Es's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne C. van Es with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne C. van Es more than expected).

Fields of papers citing papers by Suzanne C. van Es

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne C. van Es. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne C. van Es. The network helps show where Suzanne C. van Es may publish in the future.

Co-authorship network of co-authors of Suzanne C. van Es

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne C. van Es. A scholar is included among the top collaborators of Suzanne C. van Es based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne C. van Es. Suzanne C. van Es is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Oosting, Sjoukje F., Sjoerd G. Elias, Suzanne C. van Es, et al.. (2022). [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma. Clinical Cancer Research. 29(3). 592–601. 25 indexed citations
2.
Es, Suzanne C. van, Sjoerd G. Elias, Frederike Bensch, et al.. (2020). Assessment of Bone Lesions with18F-FDG PET Compared with99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. Journal of Nuclear Medicine. 62(2). 177–183. 13 indexed citations
3.
Es, Suzanne C. van, Sjoerd G. Elias, Lindsay Angus, et al.. (2020). Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.. Journal of Clinical Oncology. 38(15_suppl). 5079–5079. 1 indexed citations
4.
Elias, Sjoerd G., Suzanne C. van Es, Eline Boon, et al.. (2019). [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging. 47(4). 849–859. 19 indexed citations
5.
Es, Suzanne C. van, Bert van der Vegt, Frederike Bensch, et al.. (2019). Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. The American Journal of Surgical Pathology. 43(10). 1355–1360. 21 indexed citations
6.
Es, Suzanne C. van, Eline Boon, Lindsay Angus, et al.. (2019). Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 46(9). 1931–1939. 71 indexed citations
7.
Angus, Lindsay, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A.M. Heideman, et al.. (2019). RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer. Molecular Oncology. 13(11). 2361–2374. 33 indexed citations
8.
Bensch, Frederike, Suzanne C. van Es, Johan R. de Jong, et al.. (2018). Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse. Theranostics. 8(16). 4295–4304. 48 indexed citations
9.
Es, Suzanne C. van, Adrienne H. Brouwers, Anna M. Leliveld, et al.. (2017). 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. Journal of Nuclear Medicine. 58(6). 905–910. 48 indexed citations
10.
Hoekstra, O. S., Marc C. Huisman, Eline Boon, et al.. (2017). Imaging tumor biology with Zr-89-cetuximab, O-15-H2O and F-18-FDG PET/CT in patients with advanced colorectal cancer treated with cetuximab monotherapy. Pure Amsterdam UMC. 44. 1 indexed citations
11.
Es, Suzanne C. van, Clasina M. Venema, Andor W.J.M. Glaudemans, et al.. (2016). Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. Journal of Nuclear Medicine. 57(Supplement 1). 96S–104S. 8 indexed citations
12.
Brom, Rob R. H. van den, Suzanne C. van Es, Anna M. Leliveld, et al.. (2016). Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treatment Reviews. 46. 63–72. 9 indexed citations
13.
Oosting, Sjoukje F., Adrienne H. Brouwers, Suzanne C. van Es, et al.. (2014). 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment. Journal of Nuclear Medicine. 56(1). 63–69. 91 indexed citations
14.
Oosting, Sjoukje F., Adrienne H. Brouwers, Suzanne C. van Es, et al.. (2012). 89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.. Journal of Clinical Oncology. 30(15_suppl). 10581–10581. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kwon Joong Yong Breakdown of academic impact, for papers by Pooja Jain Breakdown of academic impact, for papers by Sietske B.M. Gaykema Breakdown of academic impact, for papers by Natalie Charnley Breakdown of academic impact, for papers by Christy Osgood Breakdown of academic impact, for papers by Atsuko Kitano Breakdown of academic impact, for papers by K. L. Blackwell Breakdown of academic impact, for papers by B. Martell Breakdown of academic impact, for papers by Ulrike Fasol Breakdown of academic impact, for papers by Masako Uno
Rankless by CCL
2026